Rikita Hatia

546 total citations
18 papers, 345 citations indexed

About

Rikita Hatia is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Rikita Hatia has authored 18 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 7 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Hepatology. Recurrent topics in Rikita Hatia's work include Liver Disease Diagnosis and Treatment (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Rikita Hatia is often cited by papers focused on Liver Disease Diagnosis and Treatment (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Rikita Hatia collaborates with scholars based in United States, Egypt and China. Rikita Hatia's co-authors include Chong‐Gee Teo, Jan Drobeniuc, D. Robert Dufour, Monica M. Parker, Bernard M. Branson, Jane P. Getchell, Saleem Kamili, John W. Ward, Michael P. Busch and Mark Pandori and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Rikita Hatia

17 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rikita Hatia United States 8 254 254 36 32 27 18 345
Tarek Besheer Egypt 13 215 0.8× 183 0.7× 76 2.1× 52 1.6× 33 1.2× 35 405
Hatem Elalfy Egypt 14 210 0.8× 189 0.7× 63 1.8× 49 1.5× 33 1.2× 39 383
Montserrat Maldonado‐González Mexico 11 332 1.3× 305 1.2× 34 0.9× 37 1.2× 9 0.3× 26 432
Zhaoxia Tan China 11 170 0.7× 180 0.7× 63 1.8× 39 1.2× 54 2.0× 27 353
Angie Price United States 8 341 1.3× 394 1.6× 69 1.9× 39 1.2× 9 0.3× 13 498
Yoichi Nishigaki Japan 8 137 0.5× 178 0.7× 42 1.2× 37 1.2× 31 1.1× 19 272
Ali Albenmousa Saudi Arabia 13 227 0.9× 234 0.9× 29 0.8× 26 0.8× 19 0.7× 32 361
Mohamed Eltabbakh Egypt 10 301 1.2× 311 1.2× 66 1.8× 34 1.1× 28 1.0× 23 443
Chun‐Ming Hong Taiwan 13 347 1.4× 339 1.3× 31 0.9× 30 0.9× 11 0.4× 34 436
Hannah M. Lee United States 11 286 1.1× 254 1.0× 43 1.2× 69 2.2× 22 0.8× 24 405

Countries citing papers authored by Rikita Hatia

Since Specialization
Citations

This map shows the geographic impact of Rikita Hatia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rikita Hatia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rikita Hatia more than expected).

Fields of papers citing papers by Rikita Hatia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rikita Hatia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rikita Hatia. The network helps show where Rikita Hatia may publish in the future.

Co-authorship network of co-authors of Rikita Hatia

This figure shows the co-authorship network connecting the top 25 collaborators of Rikita Hatia. A scholar is included among the top collaborators of Rikita Hatia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rikita Hatia. Rikita Hatia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Hatia, Rikita, Lu-Yu Hwang, Ruosha Li, et al.. (2025). Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus. Journal of Hepatocellular Carcinoma. Volume 12. 93–106. 1 indexed citations
2.
Yavuz, Betül Gök, Yehia I. Mohamed, Sunyoung S. Lee, et al.. (2024). Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. SHILAP Revista de lepidopterología. 7(4). 255–262. 3 indexed citations
3.
Xiao, Lianchun, Yehia I. Mohamed, Sunyoung Lee, et al.. (2024). Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 11. 455–461. 1 indexed citations
4.
Nguyen, Van Du, Yehia I. Mohamed, Cristhiam M. Rojas‐Hernandez, et al.. (2024). Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report. Journal of Gastrointestinal Oncology. 15(3). 1324–1330.
5.
Hatia, Rikita, Ernest T. Hawk, Ahmed Shalaby, et al.. (2023). Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiology Biomarkers & Prevention. 32(10). 1338–1347. 2 indexed citations
6.
Mohamed, Yehia I., Sunyoung S. Lee, James C. Yao, et al.. (2023). Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology. 101(11). 730–737. 2 indexed citations
7.
Mohamed, Yehia I., Dan G. Duda, Muhammad O. Awiwi, et al.. (2022). Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 13(1). 1314–1321. 10 indexed citations
8.
Day, R. Sue, Ruosha Li, Xianglin L. Du, et al.. (2021). Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients. 13(6). 2011–2011. 12 indexed citations
9.
Li, Donghui, Jiali Zheng, Rikita Hatia, Manal M. Hassan, & Carrie R. Daniel. (2021). Dietary Intake of Fatty Acids and Risk of Pancreatic Cancer: A Case-Control Study. Journal of Nutrition. 152(2). 439–447. 5 indexed citations
10.
Zheng, Jiali, Carrie R. Daniel, Rikita Hatia, et al.. (2021). Dietary N‐Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA‐Based Study. Hepatology. 74(6). 3161–3173. 15 indexed citations
11.
Day, R. Sue, Ruosha Li, Ahmed O. Kaseb, et al.. (2021). Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Medicine. 10(20). 7308–7319. 12 indexed citations
12.
Mohamed, Yehia I., Aliya Qayyum, Manal M. Hassan, et al.. (2020). IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.. Journal of Clinical Oncology. 38(15_suppl). e16660–e16660. 1 indexed citations
13.
Habra, Mouhammed Amir, Camilo Jiménez, Matthew T. Campbell, et al.. (2019). Epidemiological risk factors for adrenocortical carcinoma: A hospital‐based case–control study. International Journal of Cancer. 146(7). 1836–1840. 12 indexed citations
14.
Abdelhakeem, Ahmed, Ahmed O. Kaseb, Rikita Hatia, et al.. (2019). Distribution of insulin growth factor-1 (IGF-1) binding proteins in hepatocellular carcinoma with and without cirrhosis.. Journal of Clinical Oncology. 37(4_suppl). 193–193. 1 indexed citations
15.
Pestana, Roberto Carmagnani, Manal M. Hassan, Reham Abdel‐Wahab, et al.. (2019). Plasma GH as a diagnostic and prognostic biomarker in HCC without cirrhosis.. Journal of Clinical Oncology. 37(4_suppl). 227–227. 1 indexed citations
16.
Chapko, Michael K., D. Robert Dufour, Rikita Hatia, et al.. (2015). Cost‐effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 62(5). 1396–1404. 28 indexed citations
17.
Hatia, Rikita, et al.. (2015). Nosocomial hepatitis C virus transmission from tampering with injectable anesthetic opioids. Hepatology. 62(1). 101–110. 7 indexed citations
18.
Getchell, Jane P., Kelly Wroblewski, Alfred DeMaria, et al.. (2013). Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. MMWR Morbidity and Mortality Weekly Report. 62(18). 362–365. 232 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tarek Besheer Breakdown of academic impact, for papers by Hatem Elalfy Breakdown of academic impact, for papers by Montserrat Maldonado‐González Breakdown of academic impact, for papers by Zhaoxia Tan Breakdown of academic impact, for papers by Angie Price Breakdown of academic impact, for papers by Yoichi Nishigaki Breakdown of academic impact, for papers by Ali Albenmousa Breakdown of academic impact, for papers by Mohamed Eltabbakh Breakdown of academic impact, for papers by Chun‐Ming Hong Breakdown of academic impact, for papers by Hannah M. Lee
Rankless by CCL
2026